Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – Two weeks of headlines confirm a market sorting itself by balance sheet rather than by ambition. Cannabis is consolidating into a smaller circle of disciplined operators, while psychedelics graduate from pilot programs to checkbook-sized pharmaceutical commitments.

Capital is flowing again, rewarding strength over growth and regulatory compromises over recreational promises alone. Conventional lenders are stepping into a financing gap that private capital used to fill alone, operators are using exchange access to signal conviction in their own valuations, and global expansion has shifted from speculative land grabs to licensed, infrastructure-backed partnerships.

Psychedelics research, meanwhile, keeps broadening at the state level even as commercial activity in adjacent cannabinoid categories produces mixed results. From a Needham Bank credit line in Chicago to a genetics license in Berlin, the period delivered concrete proof that disciplined capital still finds its way into plant medicine.

1. Credit Markets Open Up for Cannabis Operators

Cresco Labs closed a $50 million revolving credit facility with Needham Bank, carrying a fixed rate below 8% and running through August 2030. That detail matters more than the headline number: federally chartered banks have historically priced Cannabis risk at a steep premium, if they would lend at all, and Cresco’s deal arrived weeks after the company registered certain medical facilities with the DEA following Schedule III rescheduling.

High Tide secured C$40 million in credit approval to fund its acquisition of Northern Helm and expand its Ontario retail footprint, extending the same pattern of operators using fresh credit lines to consolidate rather than build from scratch.

Glass House Brands took the equity route instead, filing a new shelf prospectus and doubling its at-the-market program ceiling to $100 million, with proceeds earmarked for cultivation expansion and potential acquisitions tied to the company’s bet on Schedule III export opportunities in Europe.

2. Capital Markets Access Reaches a New Threshold

Glass House Brands also applied to uplist its shares to the New York Stock Exchange, restructuring its dual-use retail business into a deconsolidated entity to satisfy exchange rules tied to the federal Controlled Substances Act. The approach mirrors the restructuring Trulieve completed earlier this month, which the NYSE approved, making Trulieve the first plant-touching Cannabis operator listed on a major American exchange.

Trulieve followed that listing almost immediately with a board-authorized share buyback program, permitting repurchases of up to $50 million or 5% of outstanding subordinate voting shares over twelve months. The combination, institutional exchange access paired with an active repurchase authorization, gives Trulieve a set of capital tools no other U.S. Cannabis operator has held before.

Quarterly and annual results filed during the window underscored the financial conditions shaping these moves. Aurora Cannabis closed its fiscal year debt-free with CA$165 million in cash and record medical Cannabis revenue, even as it guided for a harder fiscal 2027 tied to Canadian reimbursement pricing changes. Canopy Growth’s Q4 and full-year results landed in the same stretch, adding another data point to a sector where international medical demand increasingly separates growth from contraction.

Viridian Capital Advisors’ Q1 2026 Cannabis Deal Tracker put hard numbers behind the broader trend, documenting 40 capital transactions worth nearly $2 billion, up sharply from $366 million a year earlier. The report flagged more than $2 billion in unresolved Section 280E tax liability sitting across the largest MSOs, a figure that continues to separate well-capitalized acquirers from companies running out of refinancing room.

Vireo Growth’s all-stock acquisition of Nevada’s C21 Investments, which will combine the companies’ Silver State Relief dispensaries and cultivation assets into a 15-location, 158,000-square-foot footprint, is a direct expression of that consolidation logic.

Not every state’s revenue model is keeping pace with operator-level discipline. Michigan’s 24% wholesale cannabis tax generated just under $34 million in its first four months, far below the roughly $105 million per quarter lawmakers had projected, as recreational sales trailed year-ago levels and an industry trade group challenges the tax’s constitutionality in court.

3. Cannabinoid Healthcare Draws Capital from Unexpected Directions

Splash Beverage Group, a struggling consumer beverage company carrying a going-concern warning and an accumulated deficit above $155 million, completed a CDN$300,000 minority investment in Avicanna, a Toronto-based biopharmaceutical company with C$25.48 million in 2025 revenue and a 53% gross margin. The deal is small in dollar terms but directionally significant: it marks Splash’s decisive pivot away from beverages and toward cannabinoid healthcare, with management’s stated intent to pursue deeper transactions with Avicanna suggesting this stake is a positioning move rather than a terminal one.

Underlying demand for pharmaceutical-grade cannabinoid ingredients continues to expand independent of any single company’s fortunes. Verified Market Research projects the global CBD isolate market will grow from $3.2 billion in 2025 to $9.2 billion by 2033, a 14.2% CAGR driven less by consumer enthusiasm than by ingredient buyers in pharmaceuticals and nutraceuticals demanding certifiable, repeatable purity.

4. Global Expansion Moves Through Licensing, Not Ownership

Village Farms commenced cultivation at its second Dutch facility in Groningen, a build-out that will boost the company’s Netherlands production capacity fivefold [!] once it reaches full output in early 2027. The expansion follows directly from the strong uptake of Village Farms’ first Dutch facility under the country’s closed-loop coffeeshop supply experiment, where its products now reach 91% of participating retailers, and from a broader international export business that grew 171% year-over-year in Q1 2026.

Seed Junky Genetics entered the European medical Cannabis market through a licensing partnership with Green Success Group, bringing flagship strains into Germany and the UK without building cultivation or distribution infrastructure of its own. Khalifa Kush took a similar licensing path into Australia through a distribution agreement with Endoca, marking the Wiz Khalifa-founded brand’s sixth international market. Both deals point to the same underlying shift. American Cannabis brands are increasingly exporting intellectual property and reputation rather than capital, leaning on local partners who already hold the licenses and pharmacy relationships that matter in regulated medical markets.

5. Psychedelics Research Broadens at the State Level

North Carolina lawmakers united behind a bill funding psychedelic research for military veterans, joining a small but growing list of states treating psychedelic-assisted therapy as a veterans’ health priority.

Optimi’s shipment of psilocybin to the UK for a Phase 2 trial shows that clinical-stage work continues to advance internationally even as policy conversations remain concentrated in individual U.S. statehouses.

HCN Insight

Step back from the individual transactions and a coherent picture emerges. Cannabis capital markets have entered a phase where access to credit, not enthusiasm for growth, separates operators positioned to set the terms of the next two years from those who will be acquired on them.

Virginia’s compromise with recent Cannabis retail framework and Glass House’s exchange ambitions depend on regulatory patience that has, for once, worked in operators’ favor. Cresco’s bank facility and Trulieve’s buyback signal a financing environment that has begun rewarding the operators who spent the past several years building institutional-grade discipline, while Michigan’s tax shortfall is a reminder that not every market is maturing on schedule.

Meanwhile, psychedelics continues its migration from academic research to pharmaceutical balance sheet, with Otsuka’s willingness to pay $1.23 billion for a receptor-selective compound signaling that institutional capital has found a way to underwrite the category’s therapeutic promise without underwriting its full regulatory complexity. The operators and investors who read these signals correctly, prioritizing structural resilience over headline valuation, will be the ones positioned to benefit once federal rescheduling finally resolves the question every recent earnings call keeps circling back to.